{"id":"NCT03905694","sponsor":"Alnylam Pharmaceuticals","briefTitle":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","officialTitle":"ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-22","primaryCompletion":"2020-06-29","completion":"2024-07-26","firstPosted":"2019-04-05","resultsPosted":"2021-07-19","lastUpdate":"2025-02-14"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Hyperoxaluria","Primary Hyperoxaluria Type 1 (PH1)"],"interventions":[{"type":"DRUG","name":"Lumasiran","otherNames":["ALN-GO1"]}],"arms":[{"label":"Lumasiran","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).","primaryOutcome":{"measure":"Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6","timeFrame":"Baseline to Month 6","effectByArm":[{"arm":"Lumasiran","deltaMin":-71.97,"sd":2.706}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"0 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":9,"countries":["United States","France","Germany","Israel","United Kingdom"]},"refs":{"pmids":["39355649","35913563","34906487"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Pyrexia","Vomiting","Gastroenteritis","Rhinitis","Upper respiratory tract infection"]}}